SDIC Securities released a research report on April 17 stating that it gave Tianshili (600535.SH) a purchase rating, and the target price was 23.00 yuan. The main reasons for the rating include: 1) the deduction of non-net profit was in line with expectations, and the main Chinese medicine business achieved steady growth; 2) through the balance sheet and cash flow statement, the quality of the company's operations improved significantly. (Mainichi Keizai Shimbun)
国投证券4月17日发布研报称，给予天士力（600535.SH）买入评级，目标价格为23.00元。评级理由主要包括：1）扣非净利润符合预期，中药主业实现稳健增长；2）透过资产负债表和现金流量表，公司经营质量提升显著。（每日经济新闻）
SDIC Securities released a research report on April 17 stating that it gave Tianshili (600535.SH) a purchase rating, and the target price was 23.00 yuan. The main reasons for the rating include: 1) the deduction of non-net profit was in line with expectat
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.